Chief Healthcare Executive October 3, 2024
The drug giant is abandoning a plan to require hospitals to submit requests for rebates in the 340B drug discount program. The government threatened to remove the company’s drugs from Medicare and Medicaid programs.
After heavy protests from hospitals and warnings from the federal government, Johnson & Johnson has dropped its plan to require health systems to apply for rebates in the 340B drug discount program.
The drug company informed the Health Resources & Services Administration that it is dropping the plan to ask hospitals to request rebates for two popular drugs: Xarelto, a blood thinner, and Stelara, a drug for Crohn’s disease and colitis.
Under the federal 340B drug discount program, hospitals and health systems can buy certain outpatient...
Today's Sponsors
Today's Sponsor